Scarica l'app Stockscreener
3.55
1.43%
0.05
Dopo l'orario di chiusura:
3.54
-0.010
-0.28%
Precedente Chiudi:
$3.50
Aprire:
$3.46
Volume 24 ore:
345.98K
Relative Volume:
0.72
Capitalizzazione di mercato:
$108.91M
Reddito:
-
Utile/perdita netta:
$-29.25M
Rapporto P/E:
-2.9933
EPS:
-1.186
Flusso di cassa netto:
$-22.80M
1 W Prestazione:
+2.90%
1M Prestazione:
+3.80%
6M Prestazione:
-37.61%
1 anno Prestazione:
-34.26%
Intervallo 1D:
$3.32
$3.63
Intervallo di 1 settimana:
$3.32
$3.85
Portata 52W:
$1.73
$7.38
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Nome
Sagimet Biosciences Inc
Settore
Industria
Telefono
(650) 561-8600
Indirizzo
155 BOVET RD., SUITE 303, SAN MATEO
Confronta SGMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
3.55 | 111.07M | 0 | -29.25M | -22.80M | -1.186 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | Oppenheimer | Outperform |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-06-28 | Downgrade | Goldman | Buy → Neutral |
| 2024-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-25 | Iniziato | Leerink Partners | Outperform |
| 2023-08-08 | Iniziato | Goldman | Buy |
| 2023-08-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-08 | Iniziato | Piper Sandler | Overweight |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment - Investing.com Australia
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment By Investing.com - Investing.com Nigeria
Sagimet Biosciences to host KOL event on denifanstat, resmetirom - TipRanks
Sagimet Biosciences (SGMT) to Host Key Opinion Leader Event on I - GuruFocus
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating - GlobeNewswire
Leading MASH Expert to Present Groundbreaking Denifanstat-Resmetirom Combination Therapy Data - Stock Titan
Dimensional Fund Advisors LP Buys Shares of 25,334 Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
6,810 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Bought by Wells Fargo & Company MN - Defense World
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Wednesday - Defense World
Sagimet Biosciences Reports Q1 2025 Financial Results - MSN
Sagimet Biosciences, Inc.: A Promising Investment in the NASH Market with Strategic Growth Initiatives - TipRanks
Oppenheimer Revises Price Target for Sagimet Biosciences (SGMT) - GuruFocus
Oppenheimer Revises Price Target for Sagimet Biosciences (SGMT) | SGMT Stock News - GuruFocus
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Sagimet Biosciences Reports Q1 Financial Results and Updates - TipRanks
Renaissance Technologies LLC Sells 220,300 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc (SGMT) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Take off with Sagimet Biosciences Inc (SGMT): Get ready for trading - Sete News
Sagimet Biosciences announces board change - Investing.com Australia
Geode Capital Management LLC Increases Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences announces board change By Investing.com - Investing.com Nigeria
Sagimet Biosciences Inc [SGMT] Investment Appeal on the Rise - knoxdaily.com
Sagimet Biosciences Inc (SGMT)’s stock chart: A technical perspective - uspostnews.com
Insider’s View: Deciphering Sagimet Biosciences Inc (SGMT)’s Financial Health Through Ratios - DWinneX
Sagimet Biosciences Inc [SGMT] Shares Rise 8.82 % on Wednesday - knoxdaily.com
What is Sagimet Biosciences Inc (SGMT) Stock Return on Shareholders’ Capital? - Sete News
Sagimet Biosciences (SGMT) to Present Denifanstat Study Findings at EASL 2025 | SGMT Stock News - GuruFocus
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025 - GlobeNewswire
Breakthrough MASH Drug Shows Extended Phase 2b Results: 3 New Analyses Reveal Treatment Impact - Stock Titan
Sagimet Biosciences Inc (SGMT) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Predicting Sagimet Biosciences Inc’s (SGMT) earnings for the current quarter - uspostnews.com
SGMT’s Stock Market Adventure: -51.78% YTD Growth Amidst Volatility - investchronicle.com
20,103 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by American Century Companies Inc. - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Holdings of Sagimet Biosciences Inc (SGMT) are aligned with the stars - Sete News
SGMT’s Debt-to-Equity Ratio at 0.00: What It Means for Sagimet Biosciences Inc’s Future - investchronicle.com
Virtu Financial LLC Sells 9,123 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - The AM Reporter
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Consensus Price Target from Analysts - Defense World
HC Wainwright Issues Positive Estimate for SGMT Earnings - Defense World
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday - Defense World
Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position - TipRanks
HC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom - TipRanks
Sagimet Biosciences Advances MASH Treatment with New Trials - TipRanks
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet’s FASN inhibitor cleared to enter clinic for acne - BioWorld MedTech
Sagimet Biosciences Inc Azioni (SGMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):